INTRODUÇÃO: A encefalopatia hipóxico-isquêmica (EHI) corresponde a uma das maiores causas de morbidade e mortalidade neonatal. Ocorre em consequência à asfixia perinatal aguda, representada por baixo escore de Apgar e evidências de distúrbios neurológicos ao nascimento. A hipotermia terapêutica (HT) tem mostrado benefícios relevantes no prognóstico neurológico a longo prazo, por reduzir o metabolismo cerebral, retardando o início da despolarização hipóxica celular. Os efeitos da HT no sistema cardiovascular foram pouco estudados, suscitando questionamentos quanto à adequada interpretação dos achados ecocardiográficos nesta condição terapêutica. OBJETIVO: avaliar o comportamento hemodinâmico e da função ventricular de recém-nascidos com EHI na vigência de HT, utilizando-se técnicas ecocardiográficas convencionais e avançadas. MÉTODO: trata-se de um estudo observacional desenvolvido em três instituições, em que 22 recém-nascidos com EHI foram avaliados por meio da ecocardiografia nas duas fases da HT (durante a hipotermia e após o reaquecimento). O grupo controle foi composto por 22 recém-nascidos saudáveis. Os bebês foram submetidos a HT seguindo critérios do protocolo de hipotermia de cada um dos serviços. RESULTADOS: Função ventricular esquerda: as frações de ejeção (FE) e de encurtamento foram maiores após o reaquecimento (74 ± 5% e 41 ± 5% respectivamente) em relação ao grupo controle (70 ± 5%, p = 0,003 e 37 ± 4%, p = 0,002). O índice de performance miocárdica (IPM) do ventrículo esquerdo (VE) avaliado pelo Doppler pulsado se manteve constante nas duas fases da HT (0,51 ± 0,13, hipotermia = reaquecimento) e foi menor na comparação destas com o grupo controle (0,63 ± 0,18, p = 0,02). Os valores do strain circunferencial e radial, do twist, da torção e do strain longitudinal global do VE (STLGLVE) foram semelhantes entre o grupo controle e o grupo estudo, tanto durante a hipotermia quanto após o reaquecimento. Função ventricular direita: Observou-se incremento da velocidade da onda s´ do ventrículo direito (VD) após o reaquecimento (de 0,07 ± 0,02 m/s durante a hipotermia para 0,09 ± 0,01 m/s, p < 0,001), sendo esta também mais elevada quando comparada aos valores do grupo controle (0,07 ± 0,01 m/s, p < 0,001). Houve queda dos valores da variação fracional das áreas (FAC) do VD após o reaquecimento (38 ± 11% durante a hipotermia, 36 ± 11% após o reaquecimento e 43 ± 10% grupo controle), com diferenças significativas entre esses dois últimos (p = 0,03). Quanto ao IPM do VD, o grupo controle apresentou médias menores (0,29 ± 0,13) que o grupo caso durante a hipotermia (0,46 ± 0,33, p = 0,03). O strain longitudinal global do VD (STLGLVD) foi significativamente pior tanto durante a hipotermia (-18 ± -5%, p = 0,02) quanto após o reaquecimento (-18 ± 4%, p = 0,01) quando comparados ao grupo controle (-21 ± 2%). Parâmetros hemodinâmicos: A pressão sistólica na artéria pulmonar foi mais elevada no grupo estudo durante as duas fases do tratamento (hipotermia 45 ± 24 mmHg, p = 0,02 e reaquecimento 53 ± 34 mmHg, p = 0,01 versus grupo controle 29 ± 11 mmHg). A FC foi significativamente mais baixa durante a hipotermia comparada ao período após o reaquecimento (FC 111 ± 19 bpm versus 144 ± 20 bpm, p < 0,001) e ao grupo controle (FC 130 ± 16 bpm, p < 0,001). Durante o reaquecimento, observou-se elevação do débito cardíaco (DC) esquerdo e direito em relação ao período de hipotermia (DC esquerdo 214 ± 39 ml/kg/min versus 155 ± 47 ml/kg/min, p < 0,001; DC direito 369 ± 141 ml/kg/min versus 269 ± 113 ml/Kg/min, p = 0,005) sendo significativamente mais elevado que no grupo controle (DC Esquerdo 174 ± 47 ml/kg/min, p = 0,004 e DC direito 288 ± 74 ml/Kg/min, p = 0,02). CONCLUSÕES: A função ventricular esquerda permanece estável nas duas fases da HT, demonstrando o baixo comprometimento cardíaco esquerdo do resfriamento induzido. Os valores da FE, da fração de encurtamento e da onda s´ do VD, maiores após o reaquecimento, podem ser consequentes a um estado hiperdinâmico do coração. Disfunção ventricular direita foi observada nos momentos em que a pressão pulmonar estava elevada. O STLGLVD foi a única ferramenta capaz de identificar o comprometimento da função sistólica do VD durante a HT. / INTRODUCTION: The hypoxic-ischemic encephalopathy (HIE) corresponds to one of the biggest causes of neonatal morbidity and mortality. It occurs in consequence to acute perinatal asphyxia, represented by low Apgar score and evidences of neurological disorders in birth. The therapeutic hypothermia (TH) has shown significant benefits in long term neurological prognosis, by reducing the cerebral metabolism, delaying the onset of the hypoxic depolarization in cellular level. The TH effects in cardiovascular system have been insufficiently researched, raising questions regarding the adequate reading of the echocardiographic results in this condition. OBJECTIVE: to evaluate the hemodynamic and the ventricular performance of neonates with HIE submitted to TH, using conventional and advanced echocardiographic techniques. METHODS: this research is an observational study developed in three institutions, in which 22 neonates with HIE were evaluated by echocardiography in the two phases of TH (during hypothermia and after rewarming). The control group was composed by 22 healthy neonates. The infants were submitted to TH following hypothermia protocol criteria of each services. RESULTS: Left ventricular function: the ejection fraction (EF) and the shortening fraction were higher after rewarming (74 ± 5% and 41 ± 5% respectively) compared to the control group (70 ± 5%, p = 0.003 and 37 ± 4%, p = 0.002). The myocardial performance index (MPI) of the left ventricle (LV), evaluated by pulsed wave Doppler, remained constant in the two phases of TH (0.51 ± 0.13, hypothermia = rewarming) and this MPI was lower in comparison to the control group (0.63 ± 0.18, p = 0.02). The values of the circumferential and radial strain, the twist, the torsion and the global longitudinal strain (GLS) of the LV were similar between the control group and the study group, as during hypothermia as after rewarming. Right ventricular function: it was noted increment of the right ventricle (RV) s´ wave velocity after rewarming (from 0.07 ± 0.02 m/s during hypothermia to 0.09 ± 0.01 m/s, p < 0.001), also it was higher when compared to the control group (0.07 ± 0.01 m/s, p < 0.001). There was decrease of the RV fractional area change (FAC) values after rewarming (38 ± 11% during hypothermia, 36 ± 11% after rewarming and 43 ± 10% in control group), with significant differences between these two last values (p = 0.03). Regarding RV\'s MPI, the control group presented lower averages (0.29 ± 0.13) than the case group during hypothermia (0.46 ± 0.33, p = 0.03). The RV GLS was worse as during hypothermia (-18 ± -5%, p = 0.02) as after rewarming (-18 ± 4%, p = 0.01) when compared to the control group (-21 ± 2%). Hemodynamic parameters: The pulmonary artery systolic pressure was higher in the study group during the two phases of the treatment (hypothermia 45 ± 24 mmHg, p = 0.02 and rewarming 53 ± 34 mmHg, p = 0.01 versus control group 29 ± 11 mmHg). The heart rate (HR) was significantly lower during hypothermia compared to the after rewarming period (HR 111 ± 19 bpm versus 144 ± 20 bpm, p < 0.001) and to the control group (HR 130 ± 16 bpm, p < 0.001). After rewarming it was seen increase of the left and right cardiac output (CO) compared to the hypothermia period (left CO 214 ± 39 ml/kg/min versus 155 ± 47 ml/kg/min, p < 0.001; right CO 369 ± 141 ml/kg/min versus 269 ± 113 ml/Kg/min, p = 0.005), remaining significantly higher than in the control group (left CO 174 ± 47 ml/kg/min, p = 0.004 and right CO 288 ± 74 ml/Kg/min, p = 0.02). CONCLUSIONS: The LV function remains stable in the two phases of TH, showing low left cardiac impairment of the induced cooling. The values of EF, shortening fraction and RV s´ wave were higher after rewarming, possibly due to a hyperdynamic heart state. A right ventricular dysfunction was observed when the pulmonary artery systolic pressure was high. The RV GLS was the only tool able to identify the RV systolic impairment during TH.

Cardiac function is regulated by the molecular components of the sarco/endoplasmic reticulum (ER/SR). Disruptions in homeostatic balance of these proteins and calcium regulation results in activation of ER stress response. Sarcolemmal membrane-associated proteins (SLMAPs) are found in cell membrane, SR/ER, and mitochondria. Overexpression of SLMAP in the myocardium has shown to impair excitation-contraction (E-C) coupling in the transgenic (Tg) mice. ER stress response was examined in Tg mice overexpressing SLMAP in the myocardium. In Tg hearts, changes observed in the expression of proteins involved in ER stress were dependent on the age and sex. SLMAP overexpression results in maladaptive ER stress response, as the mice age. Neonatal cardiomyocytes isolated from the Tg hearts showed decreased viability, upregulation of ER stress response proteins, which were sensitized to thapsigargin-induced stress, and desensitized to palmitate-induced oxidative stress. These findings suggest that normal SLMAP levels are important for proper cardiac function, and cell viability.

L'objectif général de notre travail de thèse a été d'évaluer le rapport bénéfice/risque cardiovasculaire de l'exercice immergé. L'exercice immergé est contraignant pour le système cardiovasculaire. Il est potentiellement responsable d'une majoration de la perméabilité et/ou du gradient de pression de la barrière alvéolo-capillaire. Cet effet passe par le biais d'un accroissement des charges cardiaque et respiratoire, une sécrétion de peptides natriurétiques et une hémodilution. L'exposition au froid, la consommation d'anti-inflammatoires non stéroïdiens et la réalisation d'un exercice de forte intensité majorent le risque de survenue d'un oedème pulmonaire d'immersion. L'exercice immergé a également des effets bénéfiques. La pratique d'un sport aquatique aurait le même effet anti-hypertenseur que les activités réalisées en ambiance sèche. Par ailleurs, des différences de sollicitation endothéliale pourraient exister, en fonction des modalités d'exercice ou de la position du sujet. L'exercice immergé pourrait être plus efficace sur la perte de poids et le contrôle des facteurs de risque cardiovasculaires métaboliques, par le biais des sécrétions endocrines qu'il induit. Enfin, le réchauffement cutané associé à l'immersion dans une eau thermiquement neutre semble cardio-protecteur. / The aim of our PhD was to hold up the knowledge about risks and benefits of immersed exercise.Immersed exercise is a stress for cardiovascular system. It may result in an increase in permeability and/or pressure gradient, at the level of alveolar-capillary membrane. These effects result from an increase in cardiac and respiratory load, a natriuretic peptide secretion, and hemodilution. Exposure to cold, non-steroïdal anti-inflammatory drugs, and high intensity exercise increase the risk of a pulmonary oedema of immersion occurrence. Immersed exercise also have beneficial effects. Our observatsion suggest that immersed exercise have the hypotensive effects as ambient air exercise. Differences in endothelial stimulation may exist, depending on exercise modalities. Immersed exercise may even be more efficient on weight loss and cardiovascular risk factors control than ambient air exercise, through alterations in endocrine secretions. At the end, the global warming of the skin related to immersion in thermoneutral water appears to be cardio-protective.

A terapia celular representa uma abordagem promissora para o tratamento de cardiopatia isquêmica, porém aspectos-chave dessa estratégia permanecem incertos. Neste trabalho avaliamos a eficiência da retenção cardíaca de células da medula óssea marcadas com tecnécio (99m Tc-CMO) transplantadas, de acordo com o tempo após o infarto (1, 2, 3 e 7 dias) e a via de administração dessas células (intravenosa [IV], intraventricular [IC], intracoronariana [ICO] e intramiocárdica [IM]), em ratos submetidos à isquemia-reperfusão cardíaca [I&R]. Após 24 horas, a retenção cardíaca de 99m Tc-CMO foi maior na via IM comparada com a média alcançada pelas demais (6,79% do total injetado vs. 0,53%). O uso de fibrina como veículo para a injeção de células incrementou a retenção em 2.5 vezes (17,12 vs. 6,84%) na via IM. Curiosamente, quando administradas após 7 dias, a retenção de células na via IM alcançou valores próximos dos observados com da matriz de fibrina injetadas 24 h após a I&R (16,55 vs. 17,12%), enquanto que para as demais vias as mudanças foram insignificantes. Nos animais em que as CMO foram administradas por via intramiocárdica 24 horas após a I&R, com ou sem fibrina, observou-se melhora significante do desempenho cardíaco frente ao estresse farmacológico com fenilefrina quando comparados aos controles. Em conjunto, os dados mostram a biodistribuição das células injetadas após a I&R por 4 diferentes vias e 4 intervalos de tempo pós-lesão e indicam que a via IM é a que produz maior retenção cardíaca. O uso do biopolímero de fibrina aumenta a retenção das células e a eficácia deste efeito sobre a função cardíaca e mortalidade dos animais em longo prazo, além de 30 dias pós I&R, merecerá ser investigada no futuro. / Cell therapy represents a promising approach for ischemic cardiac disease, but key aspects of this strategy remain unclear. We examined the effects of timing and route of administration of bone marrow cells (BMCs) after myocardial ischemia/reperfusion injury (I&R). 99mTc-labeled BMCs were injected by 4 different routes: intravenous (IV), left ventricular cavity (LV), left ventricular cavity with temporal aorta occlusion (LV+) and intramyocardial (IM). The injections were performed 1, 2, 3, or 7 days after infarction. Cardiac retention was higher following the IM route compared to the average values obtained by all other routes (6.79% of the total radioactivity injected vs. 0.53%). Use of a fibrin biopolymer as vehicle during IM injection led to a 2.5-fold increase in cardiac cell accumulation (17.12 vs. 6.84%). Interestingly, the retention of cells administered with culture medium at day 7 post-MI by the IM route was similar to that observed when cells were injected 24 h post-IM using fibrin (16.55 vs 17.12%), whereas no significant changes were observed for the other routes. Cell therapy 24 hs post MI by IM injection, with or without fibrin, resulted in comparable improvement in cardiac function under pharmacological stress compared to control animals. Together, we provide evidence for the biodistribution of 99mTc-labeled BMCs injected post MI by 4 different routes and times post-injury, which shows that the IM rout is the most effective for cardiac cell retention. The use of a fibrin biopolymer further increased cardiac cell retention and its potential long term benefits, beyond 30, on reducing mortality and improving cardiac function deserve to be explored in the future.

No description available.

Cardiac rehabilitation (CR) exercise training, which traditionally involves the prescription of moderate intensity continuous exercise, can slow the progression of heart disease and improve cardiorespiratory fitness (CRF). Cardiac function is typically investigated using calculations of ejection fraction (EF) from echocardiography, yet EF measures do not provide information about the unique twisting motion of the heart. Novel measures of cardiac function, such as LV twist, myocardial performance index (MPI) and global longitudinal strain (GLS), may provide additional information about changes in LV mechanics associated with exercise training for individuals with coronary artery disease (CAD). The aims of this study were to investigate the changes in cardiac function, using both standard and novel measures, at baseline (0 weeks; T1), post-initial training (4 weeks; T2), and post-training (12 weeks; T3) in response to either stair climbing-based high intensity interval training (STAIR) or traditional moderate intensity continuous training (TRAD). We recruited 16 individuals with CAD (61±7years; 1W) and randomized them into TRAD and STAIR groups (n=8/group). Standard (CRF and EF), and novel (LV twist, MPI, GLS), measures of cardiovascular function were assessed at all three timepoints. CRF improved in both groups, after 4 and 12 weeks (STAIR: T1:22.1±4.2, T2:24.7±4.9, T3:25.4±5.2 and TRAD: T1:22.8±2.5, T2:25.2±4.9, T3:26.0±5.0 mL/kg/min; P<0.005) of CR exercise. We observed an increase in apical rotation (P=0.01) and LV twist (P=0.03), but no changes in either traditional (EF P=0.15), or novel (MPI P=0.19; GLS P=0.81) measures of cardiac function over time, in either group. It is possible that the relatively short training period (12 weeks) was not sufficient to result in significant changes in cardiac function, despite improvements in CRF. Future research should assess both standard and novel indices of cardiac function over longer exercise training periods to determine the ideal indices for tracking changes over time with interventions in this population. / Thesis / Master of Science (MSc) / Cardiac rehabilitation exercise is an important part of recovery after a heart attack, and it has been shown to improve heart function measured using standard ultrasound assessments. Studies have suggested that novel measures of heart function may be more sensitive in comparison to these standard ultrasound measures, yet these novel measures have not been examined in individuals completing stair-climbing based high intensity cardiac rehabilitation exercise training. This work examined the changes in both novel and standard ultrasound measures of heart function after either stair climbing-based high intensity interval training or traditional moderate intensity exercise training in individuals who have heart disease. While this study found that both stair climbing based high intensity interval training and traditional cardiac rehabilitation both resulted in increases in cardiorespiratory fitness after 12 weeks of training, no changes were observed in any of the standard measures of heart function. Supporting the concept that novel measures of heart function might be more sensitive, as some training associated changes were observed in the novel measures of heart function.

[ES] Las antraciclinas son fármacos antineoplásicos ampliamente utilizados en el trata-miento de varios tipos de cáncer, incluyendo tanto tumores sólidos como hematoló-gicos. A pesar de su eficacia, su uso se ve limitado por su efecto cardiotóxico. El aumento de los supervivientes de cáncer, especialmente pediátrico, ha provocado que cada vez haya más personas con cardiotoxicidad inducida por antraciclinas. Por este motivo, es necesaria la búsqueda de nuevos modelos de enfermedad relevan-tes para comprender la fisiopatología del daño cardíaco inducido por antraciclinas, así como el desarrollo de nuevas terapias cardioprotectoras que permitan el uso de las antraciclinas evitando su efecto cardiotóxico. En este trabajo se ha estudiado, por una parte, la susceptibilidad al daño por do-xorrubicina (una de las principales antraciclinas empleadas en clínica) de cardiomio-citos obtenidos a partir de células madre pluripotentes inducidas derivadas de pa-cientes pediátricos oncológicos que experimentaron cardiotoxicidad causada por an-traciclinas. Los cardiomiocitos de los pacientes fueron tratados con doxorrubicina y se evaluaron diferentes parámetros, incluyendo la viabilidad, apoptosis, estrés oxida-tivo, daño genómico, daño mitocondrial, desorganización sarcomérica, etc. compa-rándolos con cardiomiocitos control. Nuestros resultados mostraron que estos car-diomiocitos recapitulan la susceptibilidad a la doxorrubicina observada en los pacien-tes, constituyendo un buen modelo de enfermedad para estudiar los mecanismos de cardiotoxicidad de la doxorrubicina o el cribado de fármacos. Por otra parte, se ha evaluado el papel cardioprotector de un miARN, el miR-4732-3p, frente al daño inducido por antraciclinas. Este miARN está desregulado en pa-cientes con cáncer de mama que sufrieron cardiotoxicidad inducida por antraciclinas. Para comprobar su efecto cardioprotector, este miARN fue sobreexpresado en célu-las cardíacas de rata, las cuales fueron tratadas con doxorrubicina, observándose que incrementaba la supervivencia de las células y reducía el estrés oxidativo. Tam-bién se estudió la cardioprotección in vivo en un modelo de cardiotoxicidad inducida por doxorrubicina en rata, observando que mejora la función cardíaca, reduce la fi-brosis intersticial y el estrés oxidativo. Además, se hizo un estudio de los posibles genes diana de este miARN. En su conjunto, nuestros resultados muestran que el miR-4732-3p tiene un efecto cardioprotector frente al daño por doxorrubicina, y po-dría ser una herramienta terapéutica para el tratamiento del daño cardíaco causado por las antraciclinas. / [CAT] Les antraciclines són fàrmacs antineoplàstics àmpliament utilitzats en el tractament de diversos tipus de càncer, incloent tant tumors sòlids com hematològics. Tot i la seva eficàcia, el seu ús es veu limitat pel seu efecte cardiotòxic. L'augment dels su-pervivents de càncer, especialment pediàtric, ha provocat que cada cop hi hagi més persones amb cardiotoxicitat induïda per antraciclines. Per aquest motiu, cal cercar nous models de malaltia rellevants per comprendre la fisiopatologia del dany cardíac induït per antraciclines, així com el desenvolupament de noves teràpies cardiopro-tectores que permetin l'ús de les antraciclines evitant-ne l'efecte cardiotòxic. En aquest treball s'ha estudiat, d'una banda, la susceptibilitat al dany per doxorrubi-cina (una de les principals antraciclines emprades en clínica) de cardiomiòcits obtin-guts a partir de cèl¿lules mare pluripotents induïdes derivades de pacients pediàtrics oncològics que van experimentar cardiotoxicitat causada per antraciclines. Els cardi-omiòcits dels pacients van ser tractats amb doxorrubicina i es van avaluar diferents paràmetres, incloent-hi la viabilitat, apoptosi, estrès oxidatiu, dany genòmic, dany mitocondrial, desorganització sarcomèrica, etc. comparant-los amb cardiomiòcits control. Els nostres resultats van mostrar que aquests cardiomiòcits recapitulen la susceptibilitat a la doxorrubicina observada en els pacients, constituint un bon model de malaltia per estudiar els mecanismes de cardiotoxicitat de la doxorrubicina o el cribratge de fàrmacs. D'altra banda, s'ha avaluat el paper cardioprotector d'un miARN, el miR-4732-3p, davant del dany induït per antraciclines. Aquest miARN està desregulat en pacients amb càncer de mama que van patir cardiotoxicitat induïda per antraciclines. Per comprovar el seu efecte cardioprotector, aquest miARN va ser sobreexpressat en cèl·lules cardíaques de rata, les quals van ser tractades amb doxorrubicina, obser-vant-se que incrementava la supervivència de les cèl·lules i reduïa l'estrès oxidatiu. També es va estudiar la cardioprotecció in vivo en un model de cardiotoxicitat induï-da per doxorrubicina en rata, observant que millora la funció cardíaca, redueix la fi-brosi intersticial i l'estrès oxidatiu. A més, es va fer un estudi dels possibles gens di-ana d'aquest miARN. En conjunt, els nostres resultats mostren que el miR-4732-3p té un efecte cardioprotector davant el dany per doxorrubicina, i podria ser una eina terapèutica per al tractament del dany cardíac causat per les antraciclines. / [EN] Anthracyclines are drugs widely used in the treatment of several types of cancer, including both solid tumors and hematologic malignancies. Despite its proven effica-cy, its use is hampered by its cardiotoxic effect. The increase in cancer survivors, especially pediatric, has led to more and more people with anthracycline-induced cardiotoxicity. Therefore, it is necessary to search for new relevant disease models to better understand the physiopathology of cardiac damage-induced by anthracy-clines, as well as the development of new cardioprotective therapies that allow the clinic use of anthracyclines avoiding their cardiotoxic effect. In this work we have studied, on the one hand, the susceptibility against doxorubicin damage (major anthracycline used in clinic) of cardiomyocytes obtained from in-duced pluripotent stem cells derived from oncology pediatric patients that underwent cardiotoxicity-induced by anthracyclines. Cardiomyocytes from these patients were treated with doxorubicin, and we evaluated several parameters, including cell viabil-ity, apoptosis, oxidative stress, genomic damage, mitochondrial damage, sarcomere disorganization, etc. comparing the results with control cardiomyocytes. Our results showed that these cardiomyocytes recapitulate the susceptibility against doxorubicin observed in the patients, making them a good disease model to study cardiotoxicity mechanisms of doxorubicin or drug screening. On the other hand, we evaluated the cardioprotective role of one miRNA, miR-4732-3p, against doxorubicin-induced damage. This miRNA is dysregulated in breast can-cer patients that suffered cardiotoxicity-induced by anthracyclines. To test its cardio-protective effect, this miRNA was overexpressed in rat cardiac cells that were treated with doxorubicin, showing an increment of cell survival and a reduction of oxidative stress levels. We also studied in vivo cardioprotection in a doxorubicin-induced cardi-otoxicity model in rat, showing an improvement in cardiac function, reduced intersti-tial fibrosis and reduced oxidative stress levels. Moreover, we studied possible target genes of this miARN. Overall, our results showed that miR-4732-3p has a cardiopro-tective role against doxorrubicin-induced damage and could be used as a therapeutic tool for treatment of cardiac damage caused by anthracycline. / Reinal Ferré, I. (2023). Modelado de la cardiotoxicidad inducida por antraciclinas en hiPSC-CM de pacientes oncológicos pediátricos y estudio del papel cardioprotector del miR-4732-3p [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/193075

Preeclampsia is one of the leading causes of maternal and fetal mortality and morbidity. Furthermore, women who have had preeclampsia have an increased risk of cardiovascular events over the next 10-15 years. Indeed, preeclampsia is associated with a four-fold increase in the risk of hypertension and double the risk of fatal and non fatal ischaemic heart disease and stroke. In addition, offspring born to preeclampsia are more likely to have higher blood pressure from childhood and stroke in later life. The risk to mother and offspring is greatest when preeclampsia is diagnosed at an earlier gestation, suggesting a more severe form of preeclampsia. As the long term cardiovascular risk to both mother and child is known from delivery, the main interest of my research was to identify key phenotypic variations in mothers and children during the years between the episode of preeclampsia and emergence of established cardiovascular disease, which might explain the link between the two conditions. This information could then be used to devise ways to identify subjects at greatest risk of later cardiovascular disease and to establish intermediate endpoints for future preventative interventions. Therefore, in a case control study, women diagnosed with preeclampsia between 1998 and 2003 and their offspring were recruited and underwent comprehensive cardiovascular and metabolic phenotyping. Furthermore, young adults born preterm to hypertensive pregnancy were also investigated in their twenties. The research demonstrates that early-onset preeclampsia, diagnosed before 34 weeks gestation, is associated with blood pressure patterns in mothers 6-13 years after pregnancy that are distinct from those seen following later-onset disease. Furthermore, there is evidence of distinct differences in cardiac, vascular and metabolic profiles in these individuals with women having evidence of increased arterial stiffness, changes in cardiac function and reduced capillary density. Preterm offspring of hypertensive pregnancies similarly have higher blood pressure than seen in those born following late-onset disease and, in young adult life, have reduced endothelial function and changes in cardiac size proportional to this dysfunction. This research demonstrates adverse cardiac and vascular remodelling after preeclampsia in mothers and offspring that are evident before the development of clinical cardiovascular disease. The identified differences in cardiac and vascular function may be useful as surrogate endpoints in future preventive trials.

Le choc septique est associé non seulement à une réponse immunitaire excessive et inappropriée contre l'infection, mais aussi à une augmentation de l'activité nerveuse sympathique, à une augmentation des catécholamines circulantes et à un dysfonctionnement autonome. Le blocage de la bêta 1-adrénergique a montré une protection cardiovasculaire et une amélioration de la survie pendant le choc septique dans les études expérimentales et cliniques, ce qui semble être dû à ses effets anti-inflammatoires. Cependant, les effets de la réduction du rythme cardiaque (HRR) d'un bloqueur des adrénorécepteurs bêta 1 sur la fonction cardiovasculaire et les voies inflammatoires restent peu clairs. En utilisant un médicament pur de réduction du rythme cardiaque, Ivabradine, dans un modèle de choc septique polymicrobien induit par CLP, nous avons constaté que la réduction de la fréquence cardiaque : 1) n'était associé à aucune amélioration des fonctions cardiaques ou vasculaires; 2) n'avait aucun impact sur les niveaux circulants de TNF-a, IL-6 ou IL-10; 3) n'a eu aucune influence sur l'expression d'iNOS et NF-κB cardiovasculaires, les rapports P-akt / akt et P-eNOS / eNOS et la dégradation d'IκBα dans ce contexte aigu. En utilisant un bloqueur bêta 1-adrénergique, Esmolol, dans un modèle de choc septique polymicrobien induit par CLP, nous avons constaté que de faibles doses d'Esmolol, ne diminuant pas la fréquence cardiaque 1) a aussi amélioré la fonction cardiaque évaluée par échocardiographie et la vasoréactivité évaluée par myographie ; 2) les bénéfices ont été associés avec la modulation des voies inflammatoire au niveau systémique et tissulaire. Ces résultats ouvrent de nouvelles perspectives dans le traitement clinique du choc septique avec des bloqueurs adrénergiques bêta 1. / Septic shock is associated with not only an excessive and an inappropriate immune response against infection, but also with increased sympathetic nerve activity, elevated circulating catecholamines and autonomic dysfunction. Beta 1-adrenergic blockade has shown to provide cardiovascular protection and survival improvement during septic shock in experimental and clinical studies, which seems due to its anti-inflammatory effects. However, the effects of heart rate reduction (HRR) of a beta 1-adrenoreceptor blocker on cardiovascular function and inflammatory pathways remain unclear. By using a pure heart rate-lowering drug, Ivabradine, in a polymicrobial septic shock model induced by CLP, we found isolated heart rate reduction 1) was not associated with any improvement in cardiac or vascular functions; 2) has no impact on circulating levels of TNF-a, IL-6 or IL-10; 3) had no influence in cardiovascular iNOS and NF-κB expression, P-akt/akt and P-eNOS/eNOS ratio and IκBα degradations in this acute setting. By using a beta 1-adrenergic blocker, Esmolol, in a polymicrobial septic shock model induced by CLP, we found that a low dose of Esmolol, which didn’t induce HRR, also 1) improved cardiac function evaluated by echocardiography and vasoreactivity tested by myograph; 2) beneficial effects were associated with the modulation of inflammatory pathways at both the systemic and the tissue levels. These results open up new perspectives in clinical treatment of septic shock with beta 1 adrenergic blockers

Os receptores a2-adrenérgicos pré-sinápticos (a2 AR) regulam a função cardiovascular através da inibição da liberação do neurotransmissor no terminal nervoso simpático. Recentemente, foi publicado que a ablação dos subtipos a2A e a2C -AR em camundongos (KO) leva a hiperatividade simpática com evidências de disfunção cardíaca aos 4 meses de idade. Esses camundongos constituem um modelo experimental para o estudo dos tratamentos farmacológicos e não farmacológicos para a prevenção e o tratamento da insuficiência cardíaca. Nós estudamos se o treinamento físico melhoraria a função cardíaca e a expressão de proteínas cardíacas envolvidas no controle do Ca2+ intracelular em camundongos KO. Métodos e Resultados: Camundongos controle e KO foram estudados dos 3 aos 5 meses, onde a cardiomiopatia está em estágio inicial, e divididos aleatoriamente em treinados e sedentários. O treinamento físico (TF) foi realizado com natação, 1 hora por dia, 5 vezes por semana, por 8 semanas. A pressão arterial e a freqüência cardíaca de repouso (FC) foram medidas por pletismografia de cauda. A fração de encurtamento (FS) por ecocardiograma. A tolerância ao esforço físico por teste progressivo em esteira rolante. O tônus simpático cardíaco foi estimado por bloqueio farmacológico dos receptores muscarínicos e adrenérgicos com atropina na presença ou ausência do antagonista b-adrenérgico propranolol. O diâmetro dos cardiomiócitos e a fração de colágeno cardíaco por microscopia óptica. A expressão das proteínas cardíacas: bomba de Ca2+ do retículo sarcoplasmático (SERCA2), fosfolambam (PLB), fosfo-Ser16-PLB, fosfo-Thr17-PLB, trocador sódio-cálcio (NCX), canais de rianodina (RYR), fosfo-Ser2809-RYR, e as fosfatases 1 e 2A foram analisadas por Western Blot. Aos 3 meses de idade não foram observadas diferenças significantes na pressão arterial, FS e tolerância ao esforço físico entre os animais controle e KO, no entanto, KO apresentou taquicardia basal. Aos 5 meses de idade, quando a disfunção cardíaca está em estágio inicial, KO apresentou intolerância ao esforço, taquicardia basal, com aumento significante do tônus simpático cardíaco (34%), aumento do diâmetro dos cardiomiócitos (15%) e da fração de colágeno cardíaco (32%) quando comparados os animais controle. Além disso, a FS estava diminuída no KO vs. controle (16 ± 0,2 vs. 20 ± 0,9%, p<0,05). A diminuição na FS no grupo KO estava associada à redução na expressão de SERCA 2 (26%) e NCX (34%). Por outro lado, a expressão de fosfo-Ser16-PLB e fosfo-Ser2809-RYR estavam 56% e 42% aumentadas no grupo KO quando comparado ao grupo controle, respectivamente. O TF nos camundongos KO preveniu a intolerância ao esforço físico e a disfunção sistólica, normalizou a FC de repouso e o tônus simpático cardíaco, mas não alterou a fração de colágeno cardíaco. A melhora na função ventricular estava associada à restauração da expressão de SERCA2 e fosfo-Ser2809-RYR. Além disso, o TF aumentou a razão SERCA2/PLB no KO e a expressão de fosfo-Ser16-PLB no grupo KO com 5 meses de idade. Conclusão: Os dados apresentados no presente trabalho fornecem evidências de mecanismos moleculares que confirmam o benefício do treinamento físico como medida preventiva da insuficiência cardíaca. / Presynaptic a2-adrenoceptors (a2 AR) regulate the cardiovascular function by inhibiting neurotransmitter release on the sympathetic nerve terminals. We have recently reported that disruption for both a2A and a2C AR subtypes in mice (KO) leads to sympathetic hyperactivity with evidence of cardiac dysfunction by 4 mo of age. These mice provide a model system for evaluating non-pharmacological and pharmacological approaches for the prevention and treatment of heart failure. We investigated whether exercise training would improve the cardiac function and expression of myocardial Ca2+ handling proteins in KO. Methods and Results: We studied a cohort of congenic KO and their wild type (WT) controls over a period of 2 months (from 3-5 mo of age). Mice from both groups were randomly assigned into sedentary and trained. Exercise training (ET) consisted of 8-wk swimming session of 60 minutes, 5 days/wk. Blood pressure and heart rate (HR) were determined non-invasively by tail cuff. Cardiac contractility was evaluated by echocardiography. Exercise capacity was measured using a graded treadmill protocol. Cardiac sympathetic tone was estimated by pharmacological blockade of muscarinic receptors with atropine in the presence or absence of the b-adrenergic receptor antagonist propranolol. Cardiomyocyte cross-sectional diameter and cardiac collagen fraction were evaluated by optical microscopy. The protein expression of cardiac sarcoplasmic reticulum Ca2+ pump (SERCA2), phospholamban (PLB), phospho-Ser16-PLB, phospho-Thr17-PLB, sodium-calcium exchanger (NCX), ryanodine receptor (RYR), phospho-Ser2809-RYR2, and phosphatases 1 and 2A were analyzed using Western blotting technique. At 3 mo of age, no significant difference in blood pressure, FS and exercise capacity was observed between WT and KO mice, although KO mice had significantly higher HR. At 5 mo of age, when cardiac dysfunction is in an early stage, KO presented exercise intolerance and higher HR with significantly increased cardiac sympathetic tone (34%), cardiomyocyte cross-sectional diameter (15%) and cardiac collagen fraction (32%) when compared with WT mice. In addition, KO presented lower FS than WT mice (16± 0.2 vs. 20± 0.9%, p£0.05). The impaired FS in KO was associated with a reduction of SERCA2 (26%) and NCX (34%) expression. Conversely, phospho-Ser16-PLB and phospho-Ser2809-RYR2 was 56% and 42% increased in KO when compared with WT mice, respectively. ET prevented exercise intolerance and systolic dysfunction, normalized baseline HR and cardiac sympathetic tone, while it did not change cardiac collagen fraction. The improved ventricular function was associated with restored SERCA2 and phospho-Ser2809-RYR2 expression levels. Indeed, ET increased SERCA/PLB ratio and phospho-Ser16-PLB expression in 5 mo-old KO mice. Conclusion: Our data provide evidence of molecular mechanisms by which ET is a successful adjuvant to pharmacological therapy of HF.